GLP-1 RAs Offer Neuroprotection in Cerebrovascular Disorders

Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are now widely in use for treatment of type 2 diabetes and obesity. Are they useful in cerebrovascular disorders? Objective: To study the effect of GLP-1 drugs such as semaglutide and tirzepatide in the outcome of acute ischemic stroke (AIS), aneurysmal subarachnoid hemorrhage (aSAH), and spontaneous intracerebral hemorrhage (sICH). Design: Retrospective study. Methods: This study was conducted between June 2021 and December 2022, using a global platform, TriNetX Research Network. This platform has electronic health care information from 94 health care organizations, mostly in the United States, representing 141.9 million patients. Patients with AIS, aSAH, and sICH were identified from this database using ICD-10 diagnostic codes. Patients aged Results: The final number of patients after PSM were as follows: 11,810 with AIS, 751 with aSAH, and 1219 with sICH. Mean age in both groups, TG and CG, across all 3 entities was more...